Marinol

— THERAPEUTIC CATEGORIES —
  • Anorexia/cachexia
  • Nausea
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Marinol Generic Name & Formulations

    Legal Class

    CIII

    General Description

    Dronabinol 2.5mg, 5mg, 10mg; caps; contains sesame oil.

    Pharmacological Class

    Cannabinoid.

    How Supplied

    Caps—60

    Manufacturer

    AbbVie

    Generic Availability

    YES

    Marinol Indications

    Indications

    Anorexia with weight loss in AIDS patients.

    Marinol Dosage and Administration

    Adult

    Initially 2.5mg twice daily 1hr before lunch and dinner. If intolerable, may reduce to 2.5mg daily in the evening or at bedtime. May increase gradually to max 10mg twice daily. Elderly: initially 2.5mg once daily.

    Children

    Not established.

    Marinol Contraindications

    Not Applicable

    Marinol Boxed Warnings

    Not Applicable

    Marinol Warnings/Precautions

    Warnings/Precautions

    Avoid in history of psychiatric disorders (eg, mania, depression, schizophrenia); if unavoidable, monitor for new or worsening symptoms. Reduce dose or discontinue therapy if cognitive impairment develops, or if nausea, vomiting, or abdominal pain worsens. Cardiac disorders. Seizures. Substance abuse. Monitor BP, HR. Write ℞ for smallest practical amount. Keep patient under responsible adult supervision (esp. when dose is adjusted). CYP2C9 polymorphism; monitor. Elderly (monitor: esp. with dementia). Pregnancy: avoid. Nursing mothers: not recommended.

    Marinol Pharmacokinetics

    Absorption

    Dronabinol (delta-9-THC) is almost completely absorbed (90–95%) after single oral doses. Due to the combined effects of first pass hepatic metabolism and high lipid solubility, only 10–20% of the administered dose reaches the systemic circulation.

    Distribution

    Dronabinol has an apparent volume of distribution of ~10 L/kg, because of its lipid solubility. The plasma protein binding is ~97%.

    Metabolism

    Hepatic (primarily by hydroxylation). 

    Elimination

    Fecal (major), renal (10–15%). Half-life: ~4 hours (initial), ~25–36 hours (terminal).

    Marinol Interactions

    Interactions

    Avoid concomitant amphetamines, sympathomimetics, atropine, scopolamine, antihistamines, anticholinergics, TCAs. CNS depression potentiated with concomitant benzodiazepines, barbiturates, alcohol, other CNS depressants and other psychoactive substances (avoid). May potentiate concomitant highly protein-bound drugs with narrow therapeutic index (eg, warfarin, cyclosporine, amphotericin B); monitor. May be potentiated by inhibitors of CYP2C9 (eg, amiodarone, fluconazole) and CYP3A4 (eg, ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice).

    Marinol Adverse Reactions

    Adverse Reactions

    Abdominal pain, dizziness, euphoria, nausea, paranoid reaction, somnolence, abnormal thinking, vomiting; neuropsychiatric effects, hypotension, hypertension, syncope, tachycardia, seizures (discontinue if occurs).

    Marinol Clinical Trials

    See Literature

    Marinol Note

    Not Applicable

    Marinol Patient Counseling

    See Literature

    Marinol Generic Name & Formulations

    Legal Class

    CIII

    General Description

    Dronabinol 2.5mg, 5mg, 10mg; caps; contains sesame oil.

    Pharmacological Class

    Cannabinoid.

    How Supplied

    Caps—60

    Manufacturer

    AbbVie

    Generic Availability

    YES

    Marinol Indications

    Indications

    Refractory nausea and vomiting associated with cancer chemotherapy.

    Marinol Dosage and Administration

    Adult

    Give first dose on an empty stomach. Initially 5mg/m2 1–3 hrs before chemotherapy, then every 2–4 hrs after chemo; max 4–6 doses per day. May increase if needed by increments of 2.5mg/m2; max 15mg/m2 per dose. May decrease to 2.5mg once daily before chemo to reduce adverse events. Elderly: initially 2.5mg/m2 once daily.

    Children

    Not established.

    Marinol Contraindications

    Not Applicable

    Marinol Boxed Warnings

    Not Applicable

    Marinol Warnings/Precautions

    Warnings/Precautions

    Avoid in history of psychiatric disorders (eg, mania, depression, schizophrenia); if unavoidable, monitor for new or worsening symptoms. Reduce dose or discontinue therapy if cognitive impairment develops, or if nausea, vomiting, or abdominal pain worsens. Cardiac disorders. Seizures. Substance abuse. Monitor BP, HR. Write ℞ for smallest practical amount. Keep patient under responsible adult supervision (esp. when dose is adjusted). CYP2C9 polymorphism; monitor. Elderly (monitor: esp. with dementia). Pregnancy: avoid. Nursing mothers: monitor infants.

    Marinol Pharmacokinetics

    Absorption

    Dronabinol (delta-9-THC) is almost completely absorbed (90–95%) after single oral doses. Due to the combined effects of first pass hepatic metabolism and high lipid solubility, only 10–20% of the administered dose reaches the systemic circulation.

    Distribution

    Dronabinol has an apparent volume of distribution of ~10 L/kg, because of its lipid solubility. The plasma protein binding is ~97%.

    Metabolism

    Hepatic (primarily by hydroxylation). 

    Elimination

    Fecal (major), renal (10–15%). Half-life: ~4 hours (initial), ~25–36 hours (terminal).

    Marinol Interactions

    Interactions

    Avoid concomitant amphetamines, sympathomimetics, atropine, scopolamine, antihistamines, anticholinergics, TCAs. CNS depression potentiated with concomitant benzodiazepines, barbiturates, alcohol, other CNS depressants and other psychoactive substances (avoid). May potentiate concomitant highly protein-bound drugs with narrow therapeutic index (eg, warfarin, cyclosporine, amphotericin B); monitor. May be potentiated by inhibitors of CYP2C9 (eg, amiodarone, fluconazole) and CYP3A4 (eg, ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice).

    Marinol Adverse Reactions

    Adverse Reactions

    Abdominal pain, dizziness, euphoria, nausea, paranoid reaction, somnolence, abnormal thinking, vomiting; neuropsychiatric effects, hypotension, hypertension, syncope, tachycardia, seizures (discontinue if occurs).

    Marinol Clinical Trials

    See Literature

    Marinol Note

    Not Applicable

    Marinol Patient Counseling

    See Literature

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More